about
sameAs
Two-year morbidity-mortality and alternatives to prolonged breast-feeding among children born to HIV-infected mothers in Côte d'IvoireCosts of Care of HIV-Infected Children Initiating Lopinavir/Ritonavir-Based Antiretroviral Therapy before the Age of Two in Cote d'IvoireChildren who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysisSevere morbidity and mortality in untreated HIV-infected children in a paediatric care programme in Abidjan, Côte d'Ivoire, 2004-2009.Universal HIV screening at postnatal points of care: which public health approach for early infant diagnosis in Côte d'Ivoire?Estimating incidence of HIV infection in childbearing age African women using serial prevalence data from antenatal clinics.Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected childrAntiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.When do HIV-infected women disclose their HIV status to their male partner and why? A study in a PMTCT programme, Abidjan.18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission.18-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan, Côte d'Ivoire: a cohort study.Duration, pattern of breastfeeding and postnatal transmission of HIV: pooled analysis of individual data from West and South African cohortsEfavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.Growth and Mortality Outcomes for Different Antiretroviral Therapy Initiation Criteria in Children Ages 1-5 Years: A Causal Modeling AnalysisIs early detection of abused children possible?: a systematic review of the diagnostic accuracy of the identification of abused children.Intimate partner sexual and physical violence among women in Togo, West Africa: prevalence, associated factors, and the specific role of HIV infectionAntiretroviral treatment response of HIV-infected children after prevention of mother-to-child transmission in West Africa.Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan AfricaTransfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting.Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survivalEarly infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions.Preventing mother-to-child transmission of HIV-1 in Africa in the year 2000.12-month mortality and loss-to-program in antiretroviral-treated children: The IeDEA pediatric West African Database to evaluate AIDS (pWADA), 2000-2008.Scaling up antiretroviral therapy for HIV-infected children in Côte d'Ivoire: determinants of survival and loss to programme.Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d'Ivoire.Incidence of pregnancy after antiretroviral therapy initiation and associated factors in 8 West African countriesHIV status disclosure and retention in care in HIV-infected adolescents on antiretroviral therapy (ART) in West Africa.Association between age at antiretroviral therapy initiation and 24-month immune response in West-African HIV-infected childrenMissed opportunities for early access to care of HIV-infected infants in Burkina Faso[Acceptability of HIV testing provided to infants in pediatric services in Cote d'Ivoire, meanings for pediatric diagnostic coverage].Validation and calibration of a computer simulation model of pediatric HIV infectionAge-specific and sex-specific weight gain norms to monitor antiretroviral therapy in children in low-income and middle-income countries.15 Month follow up of African children following vaginal cleansing with benzalkonium chloride of their HIV infected mothers during late pregnancy and delivery.Preventing postnatal transmission of HIV-1 through breast-feeding: modifying infant feeding practicesPrevalence of malnutrition among HIV-infected children in Central and West-African HIV-care programmes supported by the Growing Up Programme in 2011: a cross-sectional study.Effect of Age at Antiretroviral Therapy Initiation on Catch-up Growth Within the First 24 Months Among HIV-infected Children in the IeDEA West African Pediatric Cohort.Effect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d'Ivoire: a prospective cohort studyTuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices.Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda.Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings.
P50
Q28469112-FEEAE094-A140-4C57-A3C6-0243F5E38FA1Q28554853-17DB1AC0-F5E1-4EB6-AB76-00AC409CB5BFQ28731813-6904AC57-AEFD-47B1-AB5E-CB9304CA8FCCQ31020587-EA8621B2-EDC6-47C3-8A90-390E912418A4Q31130109-BF4C5B38-0FF3-4C23-9C17-9C3C8632B540Q33240398-D18FFDFE-2F98-4F77-9AEF-741AE3472141Q33267065-6D4FBAF4-379E-4BF7-92C1-D7BCFC9807AFQ33294899-A262EB07-CCC5-41DC-9A41-759451A00A59Q33308259-A39F9939-EBF4-471C-806B-1C35205D0F4FQ33320539-0F5F0AF9-28BB-42A0-B888-F3DB238056D7Q33336235-C151A78D-71E0-468C-BCD0-98FAC725A00DQ33510928-378D04B4-6DEB-49E3-B385-36D404A0EA29Q33593775-CE06C1A3-A972-44AA-A6A8-D5E18D86012CQ33619587-F8221340-00DF-4283-AC78-070B5FA46179Q33643153-393100D4-C0FF-4C7E-8A0D-0268BF533FBEQ33676824-0732947D-901F-4504-B8D5-65303497AD5CQ33722976-A03D3142-0DD5-4BB3-B8A5-89E04448BC98Q33797490-5050DBD3-FB77-448E-9C58-989ECBC99B53Q33856274-8D337DC5-EF61-42A4-A589-7B994821C5D0Q33902803-35CD881F-6926-4CD4-B9ED-8DF244EF65B8Q33907111-034C09D0-685D-4948-99F9-F54AF251B0EBQ33942952-92E579E5-6CCE-4DF4-B735-C92D85CC1659Q33947235-BFA7E90B-D6BE-454A-9D0E-1FBE11BEB770Q33965572-C08C0CA4-633F-4FAA-B1D4-327EB5158893Q34078266-0490C6BD-1290-46CB-A579-2295441DD9FCQ34200073-83BFF00C-8B0A-4854-8309-CB81B7711A6BQ34211951-7BDE1CCC-35DD-48EE-8865-0236D406C823Q34214526-6E35C6E7-236B-40FD-9A4A-E78054CEADB9Q34434570-2A8D6AA5-9E8B-4C22-A629-5B345CED89C8Q34743660-2AC302A3-8239-4D7B-8FE5-972C0B024F64Q35070944-014142E6-2CA2-4C94-A9F6-AD66F2F4D19BQ35248842-B73793EB-D139-4C06-A651-1771E4602251Q35530020-1C54136A-885C-4E03-8ECB-173785CC285BQ35628422-8A01AFBF-C196-4741-8E04-E4E4C0DEB53CQ35640680-D5E9284E-00ED-4C33-AF4C-469CA87415F0Q35738443-5441CE74-C860-47C2-A563-3F45A0753655Q35739147-2766F4B2-FE8E-47A1-A248-6083DBA894ACQ35788768-E9E9C4B3-A807-4017-975D-BE158576C943Q35834097-81F13A21-FCF6-445F-97C2-82FC889A05ECQ35842613-824FF647-A10A-479E-9C54-75A9AE67AC02
P50
description
Frans onderzoekster
@nl
chercheuse française
@fr
hulumtuese
@sq
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Valeriane Leroy
@en
Valeriane Leroy
@sl
Valériane Leroy
@de
Valériane Leroy
@es
Valériane Leroy
@fr
Valériane Leroy
@gl
Valériane Leroy
@it
Valériane Leroy
@nl
Valériane Leroy
@pt
type
label
Valeriane Leroy
@en
Valeriane Leroy
@sl
Valériane Leroy
@de
Valériane Leroy
@es
Valériane Leroy
@fr
Valériane Leroy
@gl
Valériane Leroy
@it
Valériane Leroy
@nl
Valériane Leroy
@pt
altLabel
Valériane Leroy
@en
prefLabel
Valeriane Leroy
@en
Valeriane Leroy
@sl
Valériane Leroy
@de
Valériane Leroy
@es
Valériane Leroy
@fr
Valériane Leroy
@gl
Valériane Leroy
@it
Valériane Leroy
@nl
Valériane Leroy
@pt
P214
P269
P2732
P4285
P1053
F-8129-2013
P106
P21
P214
P2381
P269
P27
P2732
P2798
P31
P3829
P4285
P496
0000-0003-3542-8616
P734
P735
P7859
viaf-197167220